HQY

TentativeAI MemoPost-earnings T+3

HealthEquity

As of 2026-09-01/Post-earnings T+3/Confidence high/Horizon 6‑12m

Open ticker Back to Memos

Data freshness

AI Memo

As of 2026-09-01 • Model: RankAlpha Sentiment Codex

Decision Panel

Action, confidence, horizon, and decision blockers at a glance.

Report quality notice

peer set is too generic or lacks enough direct operating comparators; later post-earnings follow-up lacks concrete company-source and analyst/market reaction evidence

Action

—

Confidence

high

Horizon

6‑12m

Key catalyst

Q2 FY2027 earnings beat and raised outlook • 2026-08-27

Base target: $119 / p=55% prob

Biggest risk

The earnings beat was modest relative to expectations, and the initial market reaction was negative before a partial next-day rebound. Citizens maintained rather than raised its Market Outperform rating and $111 target after the print, so the analyst signal is supportive but not a strong revision catalyst. Source: Investing.com, August 28, 2026.

Invalidation

Break below $82 or thesis failure.

What would change my mind?

HQY delivered strong primary-source operating results, including record margin, accelerating HSA asset growth, higher profitability, and a raised fiscal 2027 outlook. The official release specifies fiscal 2027 revenue guidance of $1.411-$1.421 billion, non-GAAP EPS of $4.66-$4.73, and adjusted EBITDA of $628-$636 million. [#SEC-8K-2026-08-27] [#EARNINGS-TRANSCRIPT-2027Q2]

Research note

Recommendation

—

Confidence

high

As of

2026-09-01

Base target

$119

p=55%

Bull target

$135

p=25%

Bear target

$82

p=20%

Key bullets

Fast scan of bull, bear, and watch items

BullKey bullets

Post-earnings revision and reaction uncertainty
HSA account and asset growth with operating leverage
HQY delivered strong primary-source operating results, including record margin, accelerating HSA asset growth, higher profitability, and a raised fiscal 2027 outlook.

BearKey bullets

Citizens maintained its rating and target after earnings rather than raising them; broader analyst estimate revisions and target changes remain unavailable.
Recent Form 4 filings show open-market sales by director Adrian Dillon; insider activity is not direct evidence of operating performance.
[#SEC-FORM4-2026-08-27]

WatchKey bullets

Q2 FY2027 earnings beat and raised outlook

Summary

High-level snapshot

Recommendation

Model confidence

high

Timeframe

6‑12m

Asset

Equity

Trigger

Post-earnings T+3

Base case: $119 (p=55%)

Target spread vs base: +13% / -31%

Scenario probabilities

Bull Target: $135 (p=25%)Base Target: $119 (p=55%)Bear Target: $82 (p=20%)

Commentary

Primary earnings evidence is positive, supported by higher revenue, EPS, profitability, HSA assets, and raised guidance. Secondary coverage reported an initial premarket selloff followed by a next-day rebound, while Citizens maintained a Market Outperform rating and $111 target. Social coverage, options data, short-interest data, and employee-sentiment data are unavailable, so confidence remains tentative. Sources: Investing.com, August 27-28, 2026.

As of 2026-09-01 • Updated bi-weekly / post-earningsSource: Internal modelMethodology

Analyst Summary

Thesis highlights from the latest analysis

Bull Case

Bear Case

Drivers

Scannable catalysts and supporting factors

Post-earnings revision and reaction uncertainty
HSA account and asset growth with operating leverage

Scenarios

Bull Target (Scenario probability)

$135 / p=25% prob

Base Target (Scenario probability)

$119 / p=55% prob

Bear Target (Scenario probability)

$82 / p=20% prob

Analysis 2026-09-01 · RankAlpha Sentiment Codex

Analysis reference price unavailable. Targets are shown without scenario returns.

Sentiment & Exposure

News Sentiment (30d)

0.67

Social Sentiment (7d)

0.50

Events

Other notable items detected

EVENT2026-08-27
Q2 FY2027 earnings beat and raised outlook
Q2 revenue was $350.7 million, net income rose 10%, adjusted EBITDA rose 11% to $167.0 million, and adjusted EBITDA margin reached a record 48%. Non-GAAP EPS of $1.24 exceeded the Zacks consensus estimate of $1.19. Management raised fiscal 2027 guidance to revenue of $1.411-$1.421 billion, non-GAAP EPS of $4.66-$4.73, and adjusted EBITDA of $628-$636 million. [#SEC-8K-2026-08-27] [#EARNINGS-TRANSCRIPT-2027Q2]
Prob 90.00% • Move 7.00% • Priced-in 70.00%
EVENT2027-01-31
FY2027 guidance delivery checkpoint
The fiscal year ending January 31, 2027 provides a dated test of the raised revenue, non-GAAP EPS, and adjusted EBITDA outlook. [#SEC-8K-2026-08-27]
Prob 70.00% • Move 10.00% • Priced-in 45.00%
EVENT2027-04-13
Investor Day
Management scheduled the next Investor Day for April 13, 2027, creating a potential venue for longer-term strategy, product, and financial targets. [#EARNINGS-TRANSCRIPT-2027Q2]
Prob 65.00% • Move 6.00% • Priced-in 30.00%

Short-term Catalysts

Next few weeks

Post-earnings revision and reaction uncertainty
2026-11-30
Secondary coverage reported a 7.6% premarket decline on August 27 followed by a 4.4% midday gain on August 28, indicating a volatile reaction. Citizens maintained a Market Outperform rating and $111 target on August 28, but this was not an upward revision. Source: Investing.com, August 28, 2026.
Prob 55% • Move -6% • Priced-in 35%

Long-term Catalysts

Months to a year

HSA account and asset growth with operating leverage
2027-01-31
HSA accounts reached 10.7 million, total HSA assets grew 14% to $37.9 billion, and HSA investments grew 20% year over year. Continued asset growth, member engagement, and technology-enabled efficiency could support durable margin expansion. [#SEC-8K-2026-08-27] [#EARNINGS-TRANSCRIPT-2027Q2]
Prob 70% • Move 15% • Priced-in 45%

Risks

Citizens maintained its rating and target after earnings rather than raising them; broader analyst estimate revisions and target changes remain unavailable.
Recent Form 4 filings show open-market sales by director Adrian Dillon; insider activity is not direct evidence of operating performance. [#SEC-FORM4-2026-08-27]
Sustaining the record 48% adjusted EBITDA margin and continued HSA asset growth depends on execution.
The initial post-print reaction was reportedly a 7.6% premarket decline, and the subsequent rebound does not yet establish durable market confirmation.

Peers

Symbol	Summary
WEX	A more relevant benefits-account comparator than the medtech names in the packet, but no matched HQY-WEX operating metrics are available here, so relative valuation remains unverified. Source: Investing.com peer screen.
HNGE	Same-sector, similar-size healthcare technology candidate, but its operating model is not directly comparable to HQY's HSA custody and consumer-benefits platform.
HSIC	Same-sector, similar-size healthcare-services candidate; useful only as a broad reference rather than a direct operating peer.

Sources

Internal and external references used in this analysis

Model source: RankAlpha Sentiment Codex
Analysis date: 2026-09-01

Loading AI feed…

Symbol

Summary

WEX

A more relevant benefits-account comparator than the medtech names in the packet, but no matched HQY-WEX operating metrics are available here, so relative valuation remains unverified. Source: Investing.com peer screen.

HNGE

Same-sector, similar-size healthcare technology candidate, but its operating model is not directly comparable to HQY's HSA custody and consumer-benefits platform.

HSIC

Same-sector, similar-size healthcare-services candidate; useful only as a broad reference rather than a direct operating peer.